CpG 1018 augments mRNA vaccine-induced anti-tumor immunity by potentiating CD8+ T cell responses
Molecular Therapy Oncology · 2026-06 · 34 (2) · 201230
DOI: 10.1016/j.omton.2026.201230 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Therapy Oncology, 2026-06. Verfasst von Yibo Li und 6 weiteren Autor:innen. Beteiligte Einrichtung: Biomedical & Pharmaceutical Sciences, College of Pharmacy, University of Rhode Island, 7 Greenhouse Road, Avedisian Hall, Room 480, Kingston, RI 0288…. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Institutes of Health, National Science Foundation, National Institute of General Medical Sciences.
Abstract (Originalsprache)
Personalized neoantigen mRNA vaccines showed good efficacy in treating metastatic melanoma, pancreatic cancer, and breast cancer in early phase clinical trials. Strategies are needed to further enhance neoantigen mRNA vaccine-induced anti-tumor immunity. This study explored conventional adjuvant co-administration to enhance mRNA vaccine-induced anti-tumor immunity. We found a clinically used CpG 1018 adjuvant was highly effective to enhance ovalbumin (OVA) and neoantigen mRNA-induced T cell responses and anti-tumor immunity in B16F10-OVA melanoma models. Mechanistic studies found CpG 1018 mainly enhanced dendritic cell maturation and local cytokine/chemokine release but not mRNA translation. mRNA vaccine in the presence of CpG 1018 induced significantly higher levels of Granzyme B, IFNγ, and TNFα-secreting CD8+ T cells as compared to mRNA vaccine alone. We further found that potent anti-tumor immunity was associated with increased tumor-infiltration of CD8+ T cells and positively correlated with tumor-infiltrating CD8+ to CD4+ T cell ratios. Cell depletion studies found CD8+ T cells rather than CD4+ T cells or NK cells played crucial roles in CpG 1018-augmented mRNA vaccine efficacy. CpG 1018-adjuvanted mRNA vaccine induced transient body weight loss (
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Biomedical & Pharmaceutical Sciences, College of Pharmacy, University of Rhode Island, 7 Greenhouse Road, Avedisian Hall, Room 480, Kingston, RI 02881, USA.
Förderung
- National Institutes of Health
- National Science Foundation
- National Institute of General Medical Sciences
- Rhode Island College
- University of Rhode Island
Zitieren
APA
Li, Y., Nakkala, J. R., Akter, L., Kang, X., Song, Y., VanLuinen, E., & Chen, X. (2026). CpG 1018 augments mRNA vaccine-induced anti-tumor immunity by potentiating CD8+ T cell responses. Molecular Therapy Oncology, 34(2), 201230. https://doi.org/10.1016/j.omton.2026.201230
Vancouver
Li Y, Nakkala JR, Akter L, Kang X, Song Y, VanLuinen E, et al. CpG 1018 augments mRNA vaccine-induced anti-tumor immunity by potentiating CD8+ T cell responses. Molecular Therapy Oncology. 2026;34(2):201230. doi:10.1016/j.omton.2026.201230
BibTeX
@article{Li2026,
author = {Li, Yibo and Nakkala, Jayachandra Reddy and Akter, Labone and Kang, Xinliang and Song, Yuna and VanLuinen, Elise and Chen, Xinyuan},
title = {CpG 1018 augments mRNA vaccine-induced anti-tumor immunity by potentiating CD8+ T cell responses},
journal = {Molecular Therapy Oncology},
year = {2026},
volume = {34},
number = {2},
pages = {201230},
doi = {10.1016/j.omton.2026.201230}
}
EUVIMED